195 related articles for article (PubMed ID: 28484271)
1. Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin.
Suenaga G; Ikeda T; Masuda T; Motokawa H; Yamashita T; Takamatsu K; Misumi Y; Ueda M; Matsui H; Senju S; Ando Y
Sci Rep; 2017 May; 7(1):1579. PubMed ID: 28484271
[TBL] [Abstract][Full Text] [Related]
2. Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy.
Palha JA; Moreira P; Olofsson A; Lundgren E; Saraiva MJ
J Mol Med (Berl); 2001; 78(12):703-7. PubMed ID: 11434723
[TBL] [Abstract][Full Text] [Related]
3. Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools.
Kollmer J; Sahm F; Hegenbart U; Purrucker JC; Kimmich C; Schönland SO; Hund E; Heiland S; Hayes JM; Kristen AV; Röcken C; Pham M; Bendszus M; Weiler M
Neurology; 2017 Aug; 89(5):475-484. PubMed ID: 28679600
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M
Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015
[TBL] [Abstract][Full Text] [Related]
5. Serum transthyretin monomer in patients with familial amyloid polyneuropathy.
Sekijima Y; Tokuda T; Kametani F; Tanaka K; Maruyama K; Ikeda S
Amyloid; 2001 Dec; 8(4):257-62. PubMed ID: 11791618
[TBL] [Abstract][Full Text] [Related]
6. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey.
Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG
Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058
[TBL] [Abstract][Full Text] [Related]
7. Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy.
Li H; Zhang Y; Cao L; Xiong R; Zhang B; Wu L; Zhao Z; Chen SD
Drug Des Devel Ther; 2014; 8():2121-8. PubMed ID: 25382970
[TBL] [Abstract][Full Text] [Related]
8. [Application to transthyretin analysis].
Ueda M; Ando Y
Rinsho Byori; 2006 Jun; 54(6):601-8. PubMed ID: 16872010
[TBL] [Abstract][Full Text] [Related]
9. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.
Schmidt HH; Barroso F; González-Duarte A; Conceição I; Obici L; Keohane D; Amass L
Muscle Nerve; 2016 Sep; 54(3):353-60. PubMed ID: 27273296
[TBL] [Abstract][Full Text] [Related]
10. Single-centre experience on transthyretin familial amyloid polyneuropathy: case series and literature review.
Martens B; De Pauw M; De Bleecker JL
Acta Neurol Belg; 2018 Jun; 118(2):179-185. PubMed ID: 29524093
[TBL] [Abstract][Full Text] [Related]
11. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.
Sattianayagam PT; Hahn AF; Whelan CJ; Gibbs SD; Pinney JH; Stangou AJ; Rowczenio D; Pflugfelder PW; Fox Z; Lachmann HJ; Wechalekar AD; Hawkins PN; Gillmore JD
Eur Heart J; 2012 May; 33(9):1120-7. PubMed ID: 21992998
[TBL] [Abstract][Full Text] [Related]
12. Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm).
Chan GG; Koch CM; Connors LH
J Proteome Res; 2017 Nov; 16(11):4104-4112. PubMed ID: 28922609
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment.
Suenaga G; Ikeda T; Komohara Y; Takamatsu K; Kakuma T; Tasaki M; Misumi Y; Ueda M; Ito T; Senju S; Ando Y
PLoS One; 2016; 11(10):e0163944. PubMed ID: 27695122
[TBL] [Abstract][Full Text] [Related]
14. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD.
Teixeira AC; Saraiva MJ
J Cell Mol Med; 2013 Mar; 17(3):429-35. PubMed ID: 23387326
[TBL] [Abstract][Full Text] [Related]
15. Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.
Kurian SM; Novais M; Whisenant T; Gelbart T; Buxbaum JN; Kelly JW; Coelho T; Salomon DR
Theranostics; 2016; 6(11):1792-809. PubMed ID: 27570551
[TBL] [Abstract][Full Text] [Related]
16. Evidence of the presence of amyloid substance in the blood of familial amyloidotic polyneuropathy patients with ATTR Val30Met mutation.
Liu J; Lan J; Zhao P; Zheng F; Song J; Zhang P; Sun X
Int J Clin Exp Pathol; 2014; 7(11):7795-800. PubMed ID: 25550818
[TBL] [Abstract][Full Text] [Related]
17. Kidney and anemia in familial amyloidosis type I.
Beirão I; Lobato L; Costa PM; Fonseca I; Mendes P; Silva M; Bravo F; Cabrita A; Porto G
Kidney Int; 2004 Nov; 66(5):2004-9. PubMed ID: 15496172
[TBL] [Abstract][Full Text] [Related]
18. [Transthyretin familial amyloid polyneuropathy].
Kopishinskaya SV
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(10):82-89. PubMed ID: 30499502
[TBL] [Abstract][Full Text] [Related]
19. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
[TBL] [Abstract][Full Text] [Related]
20. Family dynamics in transthyretin-related familial amyloid polyneuropathy Val30Met: Does genetic risk affect family functioning?
Lopes A; Rodrigues C; Fonseca I; Sousa A; Branco M; Coelho T; Sequeiros J; Freitas P
Clin Genet; 2018 Nov; 94(5):401-408. PubMed ID: 30019395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
